BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Randal Scott sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $67.15, for a total value of $671,500.00. Following the completion of the transaction, the director directly owned 11,589 shares in the company, valued at approximately $778,201.35. This trade represents a 46.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BridgeBio Pharma Stock Up 3.4%
Shares of BBIO stock opened at $68.22 on Thursday. The company has a market cap of $13.36 billion, a price-to-earnings ratio of -18.24 and a beta of 1.02. BridgeBio Pharma, Inc. has a 52 week low of $31.77 and a 52 week high of $84.94. The firm has a 50 day moving average of $71.43 and a 200-day moving average of $71.83.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The company had revenue of $194.52 million for the quarter, compared to the consensus estimate of $178.07 million. The firm’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) EPS. Analysts anticipate that BridgeBio Pharma, Inc. will post -2.27 earnings per share for the current year.
Institutional Investors Weigh In On BridgeBio Pharma
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on BBIO shares. Citigroup started coverage on shares of BridgeBio Pharma in a report on Tuesday. They set a “neutral” rating and a $82.00 price objective on the stock. Morgan Stanley boosted their target price on BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Oppenheimer dropped their price target on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of BridgeBio Pharma in a report on Thursday, March 12th. Finally, Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the company an “outperform” rating in a report on Thursday, February 12th. Twenty-three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.90.
View Our Latest Research Report on BBIO
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Stories
- Five stocks we like better than BridgeBio Pharma
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
